Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 401–500 of 1,000
Zheng, N., 涂龙芳, Xu, P., Chen, R., Lu, J., Dai, W., Lin, Y., Ouyang, J., Qiu, J., Wang, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03845 · Cited by 2
Wang, M., Jiang, Y.-N., Li, P.-P., & Wu, Y.-J. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s565093 · Cited by 2
Thompson, K., Breaux, W., Miller, L. S., Nemeth, J. K., Koumtouzoua, S., & Travis, N. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102784 · Cited by 2
Pennycuff, J. E., Cortes-Mejia, N., Hernandez, M., Owolabi, A., Soliz, J., & Cata, J. (2026) · Anesthesia and Analgesia · doi:10.1213/ane.0000000000007967 · Cited by 2
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
Chopra, H., Mehta, A., Ponde, C., Nanda, N. C., Wander, G., Oomman, A., KERKAR, P., Routray, S., Ratnaparkhi, G., Advani, P., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1375 · Cited by 2
Slaton, R. M., Iranikhah, M. G., & White, C. W. (2026) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2026.100032 · Cited by 4
GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023
Chu, P. Y., Kelly, A., Hennessy, S., Vajravelu, M. E., Huang, J., & Amaral, S. G. (2026) · PEDIATRICS · doi:10.1542/peds.2025-071971 · Cited by 3
Advances in the Pharmacologic Management of MASLD
Madhankumar, S., & Asma, A. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17010017 · Cited by 2
“Mean weight loss was 8.5% greater than with placebo, and liver stiffness decreased as well [32].”
InfluentialGPR146 in adipose tissue drives adipose-liver crosstalk and promotes hepatic steatosis in mice
Shi, Y., Cheng, K. Y., Thi, T. T., Wang, Y., Yang, Y., Cao, X., Chhay, V., Shen, Y., He, Y., Zhao, T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70136-5 · Cited by 2
Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis
Lin, J., Huang, Y., Xu, B., Huang, C., Teng, F., Yuan, Y., Zhang, J., & Zhang, H. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70206 · Cited by 2
Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence
Yang, C.-C., Wu, J., Cheng, Y.-Y., Chang, H.-Y., Wang, S.-H., Feng, I., Kuo, H., Yu, M.-L., & Chang, W. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113206 · Cited by 2
Transplant hepatology: New epidemiology and indications
Ferrarese, A., Vivian, L. M., Martino, L., Burra, P., & Germani, G. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.01.231 · Cited by 3
Widmann, F. P., Häseli, S. P., Schattenfroh, J., Bieling, J., Jaitner, N., Muche, M., Puengel, T., Tacke, F., Asbach, P., Geisel, D., et al. (2026) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-2807-9946 · Cited by 2
Early Adoption and Prescribing Patterns of Resmetirom: A Multi‐Institutional National Analysis
Solpari, K., Gouda, Z., Saggese, A., Buckholz, A. P., Sharaiha, R. Z., Kumar, S. R., & Kushner, T. (2026) · Liver International · doi:10.1111/liv.70580 · Cited by 2
Ko, D., Kim, D. H., Tan, F. X. N., Ho, G. J. K., Chandra, R., Xuan, Z. Z., Tham, E. K. J., Tang, N. S. Y., Yang, H. S., Koh, J. W. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102614 · Cited by 3
YANG, Z., Tong, W., Zhang, K., & Guo-xin, H. (2026) · Liver Research · doi:10.1016/j.livres.2026.03.001 · Cited by 3
Semaglutide for Alzheimer's disease after evoke and evoke+
Schneider, L. S. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00514-3 · Cited by 3
Aghemo, A., Armandi, A., Bugianesi, E., Cabibbo, G., Carbone, M., D’Ambrosio, R., Dalbeni, A., Cola, S. D., Gasbarrini, A., Germani, G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.014 · Cited by 4
Self-citationMetALD at the crossroads of metabolic and alcohol-related liver disease
Ayares, G., Díaz, L. A., Arab, J. P., & Arrese, M. A. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.01.008 · Cited by 3
Alves, G. A. M., Teranishi, M., Majumdar, R., Khan, F., Dodeja, M., Ortega, A. C. T. D. C. G., Acerboni, M., Arachchige, A. S. P. M., & James, F. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70048 · Cited by 4
“…and stellate cells remains debated, clinical trial data suggest that improvements in steatohepatitis and emerging antifibrotic signals are more plausibly explained by indirect mechanisms, including reduced lipotoxicity, oxidative stress, and inflammatory cytokine signaling [9, 10, 33, 34].”
Alzaki, A. A., Alqahtani, M., Aman, E., Asiri, G. M., Jibril, M. H. A., Desoky, R. M., Alqahtani, S. A., Suhaqi, L., Alkhalid, S. A., Alshareef, D. Y., et al. (2026) · Cureus · doi:10.7759/cureus.106038 · Cited by 3
Drogy, M. S., Minto, S. T., & Frishman, W. H. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001259 · Cited by 3
Metabolic dysfunction–associated fatty liver disease: an update
O'Halloran, R. A., Adams, L. A., Deed, G., & Lubel, J. S. (2026) · Australian Prescriber · doi:10.18773/austprescr.2026.014 · Cited by 2
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment
Kozlitina, J., Romeo, S., & Hobbs, H. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001758 · Cited by 2
Mahmod, M., Dennis, A., Lian, J., Langford, C., Rahimi, K., & Wamil, M. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10629-z · Cited by 2
Albhaisi, S. A. M., Cholankeril, G. T., Kanwal, F., & Terrault, N. A. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.04.005 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
Gu, X., Luo, Y., Zhang, J., Ouyang, H., 孔紫靖, Wang, T., Huang, Z., & Ji, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117989 · Cited by 4
Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial
Pirola, C. J., & Sookoian, S. C. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.13 · Cited by 3
Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams
Alexopoulos, A., & Cusi, K. J. (2026) · Diabetes Care · doi:10.2337/dci26-0019 · Cited by 3
Heavy Drinking, Alcohol Use Disorder, and Obesity
Shuey, B., Anderson, T. S., Wharam, J. F., Liebschutz, J. M., Luo, J., Suda, K. J., & Bernstein, E. Y. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.0428 · Cited by 2
Nabilou, P., Wiese, S. S., Hetland, L. E., Werge, M. P., Rashu, E. B., Thing, M., Junker, A. E., Barløse, M., Siebner, H. R., Bendtsen, F., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-50883-7 · Cited by 2
“Shared disease mechanisms are likely to exist and metabolically active treatments such as glucagon-like peptide-1 receptor agonists (GLP-1RA) exert beneficial effects on several organs, including the liver, heart, and kidneys 7,8 .”
Recent advances in metabolic dysfunction-associated steatotic liver disease
Lonardo, A., Jamalinia, M., & Weiskirchen, R. (2026) · Eurasian Journal of Medicine and Oncology · doi:10.36922/ejmo026070085 · Cited by 3
Park, S. E., Wollstein, Y., Hutchison, A. L., & Paul, S. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09939-x · Cited by 2
Shirono, T., Iwaki, M., Seko, Y., Jun, D. W., Shima, T., Takahashi, H., Kawanaka, M., Tanaka, S., Yamaguchi, K., Yoneda, M., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.04.026 · Cited by 2
Almazan, E., Choi, J., Kamath, T., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Simon, T. G., & Chung, R. T. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004048 · Cited by 2
Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort
Ma, J., Ruderman, S. A., Haidar, L., Delaney, J. A., Kim, H. N., Alba, D. L., Crothers, K. A., Eltonsy, S., Heath, S. L., Hwang, Y. J., et al. (2026) · AIDS · doi:10.1097/qad.0000000000004544 · Cited by 2
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 3
“Furthermore, liraglutide and semaglutide have both demonstrated anti-fibrotic effects and their use in preclinical models prevents NASH-driven HCC progression (Sanyal et al., 2025; Mantovani et al., 2021).”
Teli, B., Somani, S., Arya, V., Rajput, P. J., Kahale, P., Bharmal, V. S., Shah, S., Patel, V., Ahuja, A., & PATANGE, S. A. (2026) · Cureus · doi:10.7759/cureus.108999 · Cited by 2
“Additionally, improvement in liver fibrosis without worsening steatohepatitis was observed in 36.8% of the semaglutide group compared to 22.4% in the placebo group (p 0.001) [33].”
InfluentialClinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease
Xie, C., Elfeki, M. A., Dunn, W., & Singal, A. K. (2026) · Hepatology International · doi:10.1007/s12072-026-11096-2 · Cited by 2
“Lipid profiles (LDL, HDL, total cholesterol, and tri-glycerides), blood pressure, glycemic control (homeostatic model assessment of insulin resistance and HbA1c), and weight loss (≥ 5% of baseline) are widely recognized as endpoints in clinical trials targeting metabolic diseases [53, 74].”
InfluentialJennings, I., Ly, K., Marooki, M., Dzotsi, M., McLaren, G., Cuomo, R. E., Abohashem, S., & Taub, P. R. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag279 · Cited by 2
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Qiu, H., Tan, X., Sheng, Q., Yang, N., Jiang, C. M., & Wang, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118096 · Cited by 4
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
André‐Dumont, S., & Lanthier, N. (2026) · Liver International · doi:10.1111/liv.70680 · Cited by 3
Khan, M. Q., Becchetti, C., Jouid, M. R., Mortuza, R., Panda, S., Pierluissi, V., Stegagnini, M., Punchhi, G., Bajunayd, A., Viganò, R., et al. (2026) · Liver Transplantation · doi:10.1097/lvt.0000000000000917 · Cited by 2
Plotkin, M., Ivkovic, M., Smith, I., Rathor, N., Chowdhury, R., Hodkinson, A., & Kushner, R. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70911 · Cited by 2
Cruz, A. M., Lima, B. C. V., Ferreira, J. E. D. S. M., & Teles, R. B. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04095-7 · Cited by 3
Khalil, S. M., Al‐Sharif, L., Diaz, I., & de Souza, M. H. G. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10057-x · Cited by 3
Infante, M., Ricordi, C., Pacifici, F., Pastore, D., Infante, R., Caprio, M., Chiereghin, F., Stefano, A. D., Frank, G., Rose, A. D., et al. (2026) · Nutrients · doi:10.3390/nu18132038 · Cited by 3
Mahoon, D. A., Kellany, F., Khan, I., Khan, S., & Butler, A. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125618 · Cited by 4
“This contrasted with the fibrosis benefit observed in non-cirrhotic F2–F3 MASH in ESSENCE, suggesting that fibrosis outcomes differed by baseline disease stage [25,26].”
InfluentialŠtimac, D. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102116 · Cited by 2
Saitoh, W., Shimada, T., Fukuda, D., Shibata, A., Ito, A., Otsuka, K., Okamura, H., Matoba, T., Kohro, T., Oba, Y., et al. (2026) · Circulation Reports · doi:10.1253/circrep.cr-26-0144 · Cited by 2
“11 These agents reduce body weight and visceral fat, improve inflammation and oxidative stress, Bank of Japan Inc., Tokyo (Y. Mizuno); Department of Cardiovascular Medicine (K.N.), Department of Medical Informatics (M.N.), Tohoku University Graduate School of Medicine, Sendai; Department of…”
Esteatosis hepática metabólica en el síndrome cardio-reno-metabólico: la «H» silenciada
Crespo, J., Iruzubieta, P., de Vega, T., & Calleja, J. L. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107536 · Cited by 2
Noureddin, M., Dunn, W., Patil, R., Desai, D., Puskoor, R., Shin, J., To, D., BELL, A. C., Lee, D. R., Lin, Y.-H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00130-5 · Cited by 2
KAHL, S., Caussy, C., & Cusi, K. J. (2026) · Diabetologia · doi:10.1007/s00125-026-06817-z · Cited by 2
Venkatakrishnan, A., Purushotham, K., Varma, G., Aman, A., Murugadoss, K., & Soundararajan, V. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00076-w · Cited by 2
Au, T. Y., Darekar, A., Wong, V. W., Foucquier, J., Fournier, C., Amin, N. B., & Anstee, Q. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.07.029 · Cited by 3
Weight-loss-independent actions of GLP-1 medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.07.006 · Cited by 4
Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment
Qadri, S. U. (2026) · Diabetologia · doi:10.1007/s00125-026-06816-0 · Cited by 3
MAFLD/MASLD: Past, Present, and Future
Wong, V. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70619 · Cited by 2
From liver to cardiovascular system: the MASLD–ASCVD continuum
Boccatonda, A., Bray, A., Marozzi, M. S., Cipollone, A., Lauletta, G., D’Ardes, D., Cicco, S., & Cipollone, F. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04497-6 · Cited by 3
Semaglutide and MASH resolution: A pooled analysis of recent trials
Abouelmagd, A. A., Elazab, A., Gabra, M. D., & Abosheaishaa, H. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16651 · Cited by 2
Can targeting de novo lipogenesis improve liver health?
Cabezas, M. C., & de Jong, V. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00161-x · Cited by 2
An Update on GLP ‐1 Receptor Agonists
Bloomgarden, Z. T. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70147 · Cited by 2
Liu, L. Q., Mohan, S., & Wu, L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf541 · Cited by 4
Tapper, E. B., Ryan, T., Zeng, N., Carter, R., Winer-Jones, J. P., Bonafede, M., & Kim, Y. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0223 · Cited by 2
“Improvements in cardiovascular outcomes among patients with Type 2 diabetes have been well characterized [15 , 16] , and recent clinical trials have demonstrated promising results on steatohepatitis resolution without worsening of fibrosis [17–20] .”
Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Luo, T., Liu, H., & Jin, W. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2509454 · Cited by 2
From abdominal adiposity to liver fibrosis: Expanding promise of semaglutide for Asian Indians
Ghosh, A., & Misra, A. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01881-6 · Cited by 2
Proton Density Fat Fraction and Its Role in Prediction of Metabolic Dysfunction
Reeder, S. B., & Starekova, J. (2025) · Radiology · doi:10.1148/radiol.253052 · Cited by 2
Incretin-based therapies for obesity and disordered eating: optimising care in general practice
Atlantis, E. E., Wu, R., & Dixon, J. (2026) · Family Medicine and Community Health · doi:10.1136/fmch-2025-003622 · Cited by 2
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
Razzak, I. A., Razzak, I. A., Noureddin, M., & Trivedi, H. D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002210 · Cited by 1
Lin, Y., & Wang, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117906 · Cited by 1
MetALD: new insights and unraveling therapeutic potential
Feng, Y., Han, P., Liu, T., & Gao, Y. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.65 · Cited by 1
Targeting fibrosis and steatohepatitis through the metabolism – results from the ESSENCE trial
Michel, M. S., & Schattenberg, J. M. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101492 · Cited by 3
“8,9 In light of this, the publication of the phase III ESSENCE trial marks a potential turning point in the long-lasting search for effective pharmacotherapy in non-cirrhotic MASH 10 (Fig.”
Current trends in bariatric surgery
Неймарк, А. Е., & Lapshina, S. E. (2025) · Russian surgical journal · doi:10.18705/3034-7270-2025-1-2-103-111 · Cited by 1
Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes
Béland‐Bonenfant, S., Denimal, D., de Barros, J.-P. P., Choubley, H., Rouland, A., Simoneau, I., Duvillard, L., Aho, S., Bouillet, B., Petit, J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70156 · Cited by 2
“40,41,60 Importantly, in our study, the association of baseline plasma SM d18:1/18:0 and dhCER d18:0/20:0 with AF development persisted as statistically significant even after adjusting for GLP-1 RA use during follow-up.”
AGA Institute Quality Indicators for Obesity Medication Use in Practice
Newberry, C. A., Peng, F. B., Lynch, K. L., Sheth, S. G., Pickett‐Blakely, O., & Maratt, J. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.006 · Cited by 1
Kim, Y., Zeng, N., Winer-Jones, J. P., Bonafede, M., Lobo, F., O'Donnell, J., & Ryan, T. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s546841 · Cited by 2
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?
Brennan, D. J., & Lynch, L. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0991 · Cited by 1
Segundo, R. A. D. L., & Nogueira, T. B. D. S. D. S. (2025) · COGNITIONIS Scientific Journal · doi:10.38087/2595.8801.729 · Cited by 2
GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107184 · Cited by 1
Impact of gender and age on the histologic severity of metabolic syndrome associated steatohepatitis
Acharya, E. K., Lam, R., Lim, J. K., Deng, Y., & Jain, D. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105985 · Cited by 3
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615i · Cited by 2
Impact of PNPLA3 Genotype on Hepatic Steatosis Response to Pemafibrate in MASLD With Dyslipidemia
Shirono, T., Seko, Y., Kataoka, S., Moriguchi, M., & Yamaguchi, K. (2025) · Hepatology Research · doi:10.1111/hepr.70083 · Cited by 1
Albarmawi, H., Dabbous, F., Aly, A., Yousif, A., Huse, S., Jara, M., Quintero, A., & Lawitz, E. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2596430 · Cited by 1
“The treatment of choice for most patients with MASLD and MASH has been lifestyle modification, consisting of a combination of weight loss, exercise, and improved nutrition 12 .”
InfluentialEffect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis
Anastasilakis, D. A., Anastasilakis, A. D., Gkiomisi, A. I., Semertzidis, A., Nikolakopoulos, P., Papachatzopoulos, S., Daniilidis, A., Goulis, D. G., Goulas, A., & Pοlyzos, S. A. (2025) · Endocrine · doi:10.1007/s12020-025-04511-5 · Cited by 1
GLP-1 Receptor Agonists: A New Hope in the Global Fight Against Obesity — Benefits and Health Risks
Pastuszek, O., Borowski, K., Radziwon, M., Bolesta-Okuniewska, E., Michalak, P., Marchwińska-Pancer, A., Kopeć, K., Ceryn, J., & Wicher, A. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.87.67433 · Cited by 1
Economic value and clinical association of a supervised lifestyle-improving program for MASLD
Polignano, M. G., Bianco, A., Guido, D., Trisolini, P., Franco, I., Bonfiglio, C., & Giannelli, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1708451 · Cited by 1
“…fibrosis (Harrison et al., 2024), and Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist that targets both liver disease and its underlying metabolic drivers, including obesity and insulin resistance (Sanyal et al., 2025, p. 3), no drug has yet been broadly approved for MASLD.”
Cline, L., & Wilson, E. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.09.002 · Cited by 1
Ichikawa, T., Miuma, S., Yamashima, M., Yamamichi, S., Koike, M., Nakano, Y., Yajima, H., Miyazaki, O., Ikeda, T., Okamura, T., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16020324 · Cited by 2
“The treatment of MASH has entered an era in which semaglutide [47], a drug proven effective in inducing weight loss, is employed [48].”
Wang, Y., WANG, Z., Yan, G., Peng, C., Chen, L., Yan, R., & WANG, Q. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70495 · Cited by 1
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 3
Calculating cost per event avoided using a composite number needed to treat
Toliver, J. C., Wang, J., Bhavsar, J., & Sullivan, S. D. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2615606 · Cited by 1
Anti-obesity Pharmacotherapy for Transplant Recipients
Haugen, C. E., & Orandi, B. J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01388-1 · Cited by 1
“…with MASH or hepatic fibrosis stage 2 or 3, semaglutide 2.4 mg was associated with reduction in fibrosis without worsening of steatohepatitis (36.8% of patients vs. 22.4% of patients, p 0.001) and reduction in mean body weight (-10.5% vs. -2.0%, p 0.001) compared to placebo at 72 weeks [97].”
InfluentialGlucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Patel, K. M., Jnawali, C., Zhang, J., Marsden, J. E., Bays, C., & Schreiner, A. D. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.013 · Cited by 1
Ramírez-Mejía, M. M., Ponciano‐Rodríguez, G., Poo, J. L., & Méndez‐Sánchez, N. (2026) · Archives of Medical Research · doi:10.1016/j.arcmed.2026.103387 · Cited by 1
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.